357 related articles for article (PubMed ID: 19440560)
1. White paper. The five myths of generic competition. A Pharma Matters report. March 2009.
Drug News Perspect; 2009 Apr; 22(3):171-5. PubMed ID: 19440560
[TBL] [Abstract][Full Text] [Related]
2. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
3. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
[TBL] [Abstract][Full Text] [Related]
4. A generic problem.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
[No Abstract] [Full Text] [Related]
5. The importance of being first: evidence from Canadian generic pharmaceuticals.
Hollis A
Health Econ; 2002 Dec; 11(8):723-34. PubMed ID: 12457372
[TBL] [Abstract][Full Text] [Related]
6. Strategic options for brand-name prescription drugs when patents expire.
Mehta SC; Mehta SS
Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
[TBL] [Abstract][Full Text] [Related]
7. Effect of generic drug competition on the price of prescription drugs in Ontario.
Lexchin J
CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
[TBL] [Abstract][Full Text] [Related]
8. [Discount for only one drug of the same group leads to impaired health care quality].
Bergström R
Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
[No Abstract] [Full Text] [Related]
9. Delaying generic competition--corporate payoffs and the future of Plavix.
Shuchman M
N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
[No Abstract] [Full Text] [Related]
10. Generics battle brand names over mortality of drug patents.
Betz R
J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
[No Abstract] [Full Text] [Related]
11. The impact of generic substitution on price competition in Finland.
Aalto-Setälä V
Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
[TBL] [Abstract][Full Text] [Related]
12. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
Panattoni LE
J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
[TBL] [Abstract][Full Text] [Related]
13. The impact of generic substitution on the turnover and gross margin of pharmaceutical companies a survey 1 year and 5 years after the introduction of generic substitution in Finland.
Timonen J; Karttunen P; Bengtström M; Ahonen R
Health Policy; 2009 Oct; 92(2-3):116-23. PubMed ID: 19346023
[TBL] [Abstract][Full Text] [Related]
14. Competition body rules that drug companies "abused" their position.
Sidley P
BMJ; 2003 Oct; 327(7421):946. PubMed ID: 14576226
[No Abstract] [Full Text] [Related]
15. Are we living in the end of the blockbuster drug era?
Debnath B; Al-Mawsawi LQ; Neamati N
Drug News Perspect; 2010 Dec; 23(10):670-84. PubMed ID: 21180653
[TBL] [Abstract][Full Text] [Related]
16. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
17. Price regulation and generic competition in the pharmaceutical market.
Dalen DM; Strøm S; Haabeth T
Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
[TBL] [Abstract][Full Text] [Related]
18. Reference pricing of pharmaceuticals.
Brekke KR; Königbauer I; Straume OR
J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
[TBL] [Abstract][Full Text] [Related]
19. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
20. Overcoming the challenges in the pharma/biotech industry.
Graul AI; Prous JR
Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
